William A. Newton

TL;DR: The authors conclude that for the therapeutic regimens evaluated there was no therapeutic advantage to including radiation in the treatment of Clinical Group I disease, or cyclophosphamide given as a daily low‐dose oral regimen in thetreatment of clinical Group II disease or Adriamycin in the Treatment of Clinical Groups III and IV diseases.

TL;DR: Histopathologic prognostic factors of 295 pretreatment tumors of a total 641 neuroblastomas and ganglioneuroblastomas were studied with the use of the following proposed tumor classification.

TL;DR: There is a substantial excess of second neoplasms, especially of the central nervous system, among children treated for ALL, and children five years old or younger and those receiving radiation are at higher risk, especially for second tumors arising in thecentral nervous system.

TL;DR: There is no indication as yet that one treatment regimen is superior to the other in the Intergroup Rhabdomyosarcoma Study, and over 85% of patients on either treatment have no evidence of disease and 90% are still alive.

TL;DR: There was close agreement between the review committee and institutional pathologists in the diagnosis of RMS, but not in the specific types, particularly Alv RMS and STI, and the prognosis varied by histology, with Botr having the best, Alv R MS andSTI the worst, and Emb RMSand EOE an intermediate prognosis.